Jupiter Asset Management Ltd. Cuts Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD
Jupiter Asset Management Ltd. significantly reduced its stake in ACADIA Pharmaceuticals Inc. by 25.2% in the third quarter of 2025, selling over 160,000 shares. Other institutional investors showed mixed activity, with some increasing and others decreasing their holdings. The biopharmaceutical company is trading at $23.99, with a consensus "Moderate Buy" rating from Wall Street analysts and an average target price of $30.95.
ACADIA Pharma Stock: What Wall Street Missed in the Latest Drop
ACADIA Pharmaceuticals is a high-conviction, high-volatility stock in the neurology and rare-disease sector, and despite recent price drops, Wall Street remains largely bullish. The company is transitioning from a single-product focus to a broader portfolio strategy, with its future valuation largely dependent on successful pipeline execution and potential M&A. Investors should consider ACADIA as a satellite growth holding, understanding the associated biotech-style volatility and aligning their investment horizon with the Street's multi-year outlook.
ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome
ACADIA Pharmaceuticals (ACAD) is approaching a crucial Phase 3 readout for its drug trofinetide in patients with Prader-Willi Syndrome, a rare genetic disorder. This oral therapy has already received FDA approval for Rett Syndrome, and a positive outcome in the Prader-Willi trial could significantly expand its market potential and valuation for ACAD. The trial's success would open up a new indication for the drug and address a high unmet medical need.
LSV Asset Management Sells 192,800 Shares of ACADIA Pharmaceuticals Inc. $ACAD
LSV Asset Management significantly reduced its stake in ACADIA Pharmaceuticals Inc. by selling 91.8% of its shares, retaining 17,200 shares. Despite this large sale, institutional ownership in ACADIA remains high at 96.71%, with other funds like Marshall Wace and Norges Bank increasing or initiating their positions. Analysts maintain a "Moderate Buy" rating for ACADIA with a consensus price target of $30.95.
Public Sector Pension Investment Board Has $10.39 Million Holdings in ACADIA Pharmaceuticals Inc. $ACAD
The Public Sector Pension Investment Board increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 15.3% in the third quarter, bringing its total holdings to 486,988 shares valued at $10.39 million. While institutional investors own a significant portion of the stock, an executive vice president recently sold a large portion of her shares. Analysts currently rate ACADIA as a "Moderate Buy" with a consensus price target of $31.30.
15 Innovative Healthcare Stocks to Buy According to Analysts
The article lists 15 innovative healthcare stocks recommended by analysts, highlighting ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) as an example. It details Oppenheimer's bullish outlook and price target raise for ACAD, despite a setback regarding regulatory approval for its Rett syndrome treatment in Europe. The article also mentions the company's commitment to patients and ongoing collaboration with regulatory bodies.
ACADIA Pharmaceuticals (ACAD) Is Down 6.5% After CHMP Negative Trend Vote on Rett Drug DAYBUE
ACADIA Pharmaceuticals experienced a 6.5% stock drop after the EMA’s CHMP issued a negative trend vote on its Marketing Authorization Application for DAYBUE in Rett syndrome, prompting the company to seek re-examination. This regulatory hurdle in Europe contrasts with the drug's recent U.S. FDA approval for a new formulation, highlighting differing market challenges. Despite this setback, ACADIA's broader investment narrative continues to focus on its CNS and rare-disease franchise growth, with future earnings and guidance being key catalysts.
ACADIA Pharmaceuticals (ACAD) Is Down 6.5% After CHMP Negative Trend Vote on Rett Drug DAYBUE
ACADIA Pharmaceuticals (ACAD) shares dropped 6.5% following a negative trend vote from the EMA's CHMP regarding its Marketing Authorization Application for trofinetide (DAYBUE) for Rett syndrome in Europe. The company plans to seek a re-examination, highlighting regulatory hurdles despite the drug's availability elsewhere. This setback introduces uncertainty, contrasting with the recent FDA approval of a new DAYBUE formulation meant to broaden its U.S. use.
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness
ACADIA Pharmaceuticals has experienced recent share price weakness, with short-term declines, despite a positive one-year return. The company, which focuses on central nervous system disorders, is valued by Simply Wall St at $31.21 per share against a market price of $22.47, suggesting it is undervalued due to its pipeline momentum and anticipated revenue and earnings growth. However, there are risks associated with its reliance on NUPLAZID and potential margin squeeze from R&D spending.
Understanding Momentum Shifts in (ACAD)
Acadia Pharmaceuticals Inc. (ACAD) is showing weak near and mid-term sentiment, despite a strong long-term positive outlook. AI models have generated distinct trading strategies, including long, breakout, and risk hedging options, alongside multi-timeframe signal analysis. The current price of ACAD is situated between support and resistance levels, with elevated downside risk in the absence of additional long-term support.
Candriam S.C.A. Buys New Stake in ACADIA Pharmaceuticals Inc. $ACAD
Candriam S.C.A. has initiated a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), purchasing 537,601 shares valued at approximately $11.47 million in the third quarter. This move, along with increased stakes from other institutional investors like Marshall Wace LLP, signifies strong institutional interest, bringing total institutional ownership to about 96.71%. Despite insider selling, analysts maintain a "Moderate Buy" consensus rating for ACADIA with a price target of $31.30.
ACADIA Pharmaceuticals Inc. (ACAD): Investor Outlook Reveals 34% Upside Potential Amid Robust CNS Pipeline
ACADIA Pharmaceuticals (NASDAQ: ACAD) is attracting investor attention with a $3.93 billion market cap and a strong pipeline for CNS disorders and rare diseases, including its flagship product NUPLAZID and DAYBUE for Rett Syndrome. Analysts predict a 34.41% upside potential from the current stock price, driven by positive sentiment, strategic collaborations, and upcoming Phase III trial results for pimavanserin and ACP-101. Despite no dividend, the company's focus on innovation positions it as a growth opportunity in the healthcare sector.
Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 6,950 Shares of Stock
ACADIA Pharmaceuticals EVP Jennifer Rhodes sold 6,950 shares of the company's stock on February 9th, reducing her position by nearly half. The transaction, valued at $162,491, left her with 7,609 shares. ACADIA Pharmaceuticals stock traded down 2.2% following the news, with a market capitalization of $3.84 billion and an average analyst rating of "Moderate Buy."
ACADIA Pharmaceuticals: Biotech Optimism Meets Volatile Reality After A Sharp Pullback
ACADIA Pharmaceuticals (ACAD) has experienced a recent stock pullback, yet long-term holders still retain significant profits. The company, which specializes in neuroscience and rare diseases, is at a crossroads where Wall Street analysts are cautiously optimistic, highlighting its Parkinson's psychosis drug and expanding pipeline. Investors are weighing recent quarterly results and pipeline developments against short-term volatility to determine if the stock is a recovery play or facing continued challenges.
Acadia Pharmaceuticals Shares Drop After Phase 3 PWS Trial Misses Primary Goal
Acadia Pharmaceuticals' shares experienced a significant drop after its Phase 3 trial for trofinetide in Prader-Willi Syndrome (PWS) failed to meet its primary endpoint. Despite the setback, the company stated it will continue to analyze the data and discuss next steps with the FDA. This news follows a previous success for trofinetide in Rett Syndrome.
Acadia Pharmaceuticals stock price target raised to $23 from $21 at Oppenheimer
Oppenheimer raised its price target for Acadia Pharmaceuticals (NASDAQ:ACAD) to $23 from $21, while maintaining an Outperform rating, based on the company's long-term revenue projections of $1.7 billion by 2028. This outlook includes significant contributions from Nuplazid and Daybue sales, despite a recent setback for trofinetide's European approval. The company is also anticipating key Phase 2/3 and Phase 3 data readouts for other pipeline candidates.
ACADIA Pharmaceuticals (ACAD) Is Down 5.5% After EMA Trend Vote Goes Against Daybue In Europe
ACADIA Pharmaceuticals (ACAD) shares dropped 5.5% after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote against trofinetide (Daybue) for treating Rett syndrome in Europe. This decision impacts Acadia's international expansion for Daybue, which is already approved in the US, Canada, and Israel. The company plans to request a formal re-examination in the EU, and this setback shifts investor focus to the US market performance of Daybue and Nuplazid.
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it will report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time, accessible via its website or by registration. Acadia is focused on developing therapies for underserved neurological and rare diseases.
European regulators unlikely to recommend approval of Daybue
Acadia Pharmaceuticals faces a setback in Europe as regulators are unlikely to recommend approval for its Rett syndrome drug, trofinetide (Daybue). Despite approvals in the U.S., Canada, and Israel, the Committee for Medicinal Products for Human Use (CHMP) has indicated a negative trend vote. Acadia plans to request a reexamination of the application, emphasizing its commitment to making the therapy available in the EU.
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it will report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and provide business updates. Acadia is focused on developing treatments for underserved neurological and rare disease communities, with a robust pipeline in conditions like Alzheimer's disease psychosis and Lewy body dementia psychosis.
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) has been identified as a strong value stock through a "Decent Value" screen, indicating it is potentially mispriced with solid underlying fundamentals. The company exhibits a competitive valuation compared to peers, strong financial health with no debt, and impressive earnings evidenced by high margins and returns on capital. Furthermore, ACADIA shows significant expansion with high revenue growth and strong future EPS forecasts, suggesting it is a growing company available at a discount.
ACADIA Pharmaceuticals (ACAD) Is Down 5.5% After EMA Trend Vote Goes Against Daybue In Europe
ACADIA Pharmaceuticals' stock dropped 5.5% after the European Medicines Agency's committee issued a negative trend vote for its Rett syndrome drug Daybue, even though it's approved in other regions. The company plans to request a re-examination, and this European setback could shift investor focus to Daybue's US performance and other pipeline assets, while highlighting regulatory risks outside the US. The article also notes a wide range of fair value estimates for ACAD, suggesting potential for further downside despite the recent dip.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has received a consensus "Moderate Buy" rating from twenty brokerages, with an average 12-month price target of $31.25. The company recently exceeded earnings expectations, reporting $0.42 EPS against a $0.14 consensus and revenue of $278.63 million, an 11.3% year-over-year increase. Insider activity shows sales of approximately 44,346 shares ($1.01M) over the past 90 days, while institutional investors hold a significant 96.7% stake.
A Glimpse Into The Expert Outlook On ACADIA Pharmaceuticals Through 11 Analysts
Eleven analysts have provided ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD) within the last three months, with an average 12-month price target of $32.82, up from $31.73. The article details individual analyst actions, including rating changes and price target adjustments, and provides key financial insights into ACADIA Pharmaceuticals' market capitalization, revenue growth, net margin, and return metrics. It also explains the basics of analyst ratings and their significance for investors.
EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug
An EU panel rejected Acadia Pharmaceuticals' Marketing Authorization Application for trofinetide, a Rett syndrome drug. Despite approvals in the U.S., Canada, and Israel, the Committee for Medicinal Products for Human Use (CHMP) issued a negative vote. Acadia plans to request a re-examination of the decision, emphasizing the drug's demonstrated benefits for a condition that previously had no approved treatment.
The Bull Case For ACADIA Pharmaceuticals (ACAD) Could Change Following EMA Setback For Trofinetide Approval
ACADIA Pharmaceuticals faces a potential shift in its investment outlook after the European Medicines Agency (EMA) issued a negative trend vote for its Rett syndrome drug, trofinetide. This decision complicates the company's international growth strategy, placing increased importance on its US operations and pipeline diversification. Investors are now re-evaluating the company's valuation and the inherent regulatory and concentration risks.
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Strong One Year Share Price Gain?
ACADIA Pharmaceuticals (ACAD) has seen a 41.2% return over the past year, currently trading at US$26.13. Despite a 49.0% decline over five years, analyses suggest the stock is significantly undervalued, with a Discounted Cash Flow model indicating an 81.4% undervaluation and its P/E ratio being below industry averages. The article encourages investors to use "Narratives" on Simply Wall St to compare different valuation perspectives and stay updated on the company's performance.
CHMP signals negative stance on Acadia's Rett syndrome drug ahead of opinion
The CHMP has signaled a negative stance on Acadia's trofinetide for Rett syndrome, indicating a likely unfavorable opinion. This will be the second time the drug has faced a negative opinion from the European regulator. The final decision is expected this week.
Acadia Pharma down after negative EU trend vote on neurological disorder drug
Acadia Pharmaceuticals (ACAD) saw its stock price fall following a negative trend vote from the European Union regarding its drug for a neurological disorder. The news was reported by Reuters and indicates a setback for the company's European market aspirations.
Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again
Acadia Pharmaceuticals (ACAD) is projected to beat its upcoming earnings estimates, continuing a trend of exceeding expectations in its previous two reports. The company has an average earnings surprise of 50.00% over the last two quarters. Its positive Zacks Earnings ESP of +14.92% combined with a Zacks Rank #3 (Hold) indicates a strong likelihood of another earnings beat.
ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug
ACADIA Pharmaceuticals (NASDAQ:ACAD) stock dropped 4.4% after European regulators issued a negative preliminary opinion on the company’s Rett syndrome treatment, trofinetide. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) provided an unfavorable initial review for the Marketing Authorization Application. ACADIA plans to request a re-examination, emphasizing the drug's approved status and benefits in the U.S., Canada, and Israel.
ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug
Acadia Pharmaceuticals (ACAD) shares dropped over 8% after-hours following a negative trend vote from a European Medicines Agency committee regarding its drug Trofinetide for Rett syndrome. Despite the setback, which CEO Catherine Owen Adams called "disappointing," the company plans to request a re-examination of the decision. Trofinetide is already approved in the US, Canada, and Israel for treating Rett syndrome, a rare genetic neurological disorder.
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Acadia Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative trend vote on its Marketing Authorization Application for trofinetide, a treatment for Rett syndrome, after an oral explanation. Despite this, Acadia intends to request a re-examination, citing strong data supporting U.S., Canadian, and Israeli approvals and positive real-world outcomes. The company remains committed to making trofinetide available to the Rett syndrome community in the EU.
Universal Beteiligungs und Servicegesellschaft mbH Lowers Holdings in ACADIA Pharmaceuticals Inc. $ACAD
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in ACADIA Pharmaceuticals Inc. by 58.0% during the third quarter, now holding 47,094 shares valued at $1,005,000. This move comes alongside other institutional and insider trading activities, with several hedge funds adjusting their positions and company insiders selling shares worth over $1 million in the last three months. ACADIA Pharmaceuticals reported strong Q3 earnings, beating analyst estimates for both EPS and revenue, maintaining a "Moderate Buy" consensus rating from analysts with an average price target of $31.16.
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness
ACADIA Pharmaceuticals (ACAD) has experienced recent share price weakness, with declines over the past day, week, and month, despite a 3-month total return of 10.7% and a 1-year return of 34.7%. The article examines whether the current price of US$25.13 presents a potential entry point, noting that a detailed cash flow analysis suggests ACADIA is 18.2% undervalued, with a fair value of $30.74 due to its pipeline momentum and potential for diversified revenue streams. This valuation, however, is contingent on managing risks like heavy reliance on NUPLAZID revenue and rising R&D costs.
Privium Fund Management B.V. Sells 78,000 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Privium Fund Management B.V. significantly reduced its stake in ACADIA Pharmaceuticals Inc. by selling 78,000 shares in Q3, now holding 70,400 shares worth $1.502 million. This move comes amidst other institutional investors either increasing their positions or initiating new ones, indicating varied sentiment towards the biopharmaceutical company. ACADIA Pharmaceuticals recently beat quarterly earnings expectations and has an average "Moderate Buy" rating from analysts with an average price target of $31.16.
Great Lakes Advisors LLC Sells 333,245 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Great Lakes Advisors LLC reduced its stake in ACADIA Pharmaceuticals Inc. by 42.3% during the third quarter, selling 333,245 shares and retaining 454,790 shares valued at about $9.71 million. Despite this sale, institutional investors own 96.71% of the stock, and analysts maintain a "Moderate Buy" rating with an average target price of $31.16. ACADIA Pharmaceuticals recently reported strong Q3 earnings, exceeding revenue and EPS expectations.
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: 14.83% Potential Upside In CNS And Rare Disease Biotech
ACADIA Pharmaceuticals Inc. (ACAD) shows a potential upside of 14.83% with an average target price of $30.84, driven by its focus on CNS disorders and rare diseases. The company boasts significant revenue growth (11.30%) and return on equity (34.95%), alongside a robust pipeline including NUPLAZID and DAYBUE. Analyst ratings are largely positive, with 13 buy ratings, indicating confidence in ACADIA's strategic direction and growth opportunities in the biotechnology sector.
Acadia Pharmaceuticals stock undervalued with $32 price target, says Canaccord By Investing.com
Canaccord Genuity has reiterated a Buy rating and a $32.00 price target for Acadia Pharmaceuticals (NASDAQ:ACAD), considering the company undervalued based on its approved products and pipeline potential. The firm cited an expectation of $1.7 billion in combined sales from Nuplazid and Daybue by 2028, significantly higher than its current annual revenue. Upcoming catalysts include a CHMP opinion on Daybue in Europe and Phase 2 RADIANT study data for remlifanserin for Alzheimer's disease psychosis.
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and ACADIA Pharmaceuticals (ACAD)
RBC Capital analysts have provided bullish sentiments on two healthcare companies: Boston Scientific (BSX) and ACADIA Pharmaceuticals (ACAD). Shagun Singh Chadha maintained a Buy rating on Boston Scientific with a $130.00 price target, while Brian Abrahams maintained a Buy rating on ACADIA Pharmaceuticals with a $35.00 price target. Both stocks currently show significant upside potential based on analyst consensus.
H.C. Wainwright Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37
H.C. Wainwright analyst Ananda Ghosh has reiterated a Buy rating for ACADIA Pharmaceuticals (ACAD.US), maintaining a target price of $37. According to TipRanks data, the analyst has a 66.7% success rate and an average return of 74.3% over the past year. This information is intended for informational purposes only and does not constitute investment advice.
Discipline and Rules-Based Execution in ACAD Response
This article analyzes Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) using AI models, identifying weak near- and mid-term sentiment but a strong long-term outlook. It provides specific trading strategies—position trading, momentum breakout, and risk hedging—with entry, target, and stop-loss levels, and outlines support and resistance signals across different time horizons. The analysis emphasizes rules-based execution and risk management in responding to ACAD's market signals.
Campbell & CO Investment Adviser LLC Takes $838,000 Position in ACADIA Pharmaceuticals Inc. $ACAD
Campbell & CO Investment Adviser LLC initiated a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), purchasing 39,286 shares valued at approximately $838,000 in the third quarter. Despite recent insider sales totaling $1.01 million, institutional investors hold a dominant 96.71% ownership, and analysts maintain a "Moderate Buy" consensus with an average target of $31.16, with some firms raising targets after strong Q3 earnings.
Assessing Acadia Pharmaceuticals (ACAD) Valuation After New Long Term Sales And Pipeline Targets
Acadia Pharmaceuticals (ACAD) recently outlined ambitious long-term sales targets, projecting net sales above US$1 billion by 2025 and US$1.7 billion by 2028, driven by its neurology portfolio. Despite strong recent share price performance, the stock is currently assessed as 15.4% undervalued compared to the most followed narrative's fair value of $30.74, suggesting a potential buying opportunity. This valuation accounts for Acadia's pipeline of nine programs and expected late-stage clinical readouts by 2027, which aim to diversify revenue streams, though potential pricing pressure on NUPLAZID or pipeline setbacks remain risks.
Assessing Acadia Pharmaceuticals (ACAD) Valuation After New Long Term Sales And Pipeline Targets
Acadia Pharmaceuticals (ACAD) recently updated its long-term sales targets, anticipating over US$1 billion by 2025 and approximately US$1.7 billion by 2028, driven by its neurology portfolio. Despite recent stock momentum and a 47.9% annual return, the stock is considered 15.4% undervalued compared to a fair value of US$30.74, according to analyst narratives. The company's pipeline of 9 disclosed programs is expected to diversify revenue streams, though potential risks like pricing pressure on NUPLAZID or pipeline setbacks remain.
Investing in ACADIA Pharmaceuticals (NASDAQ:ACAD) a Year Ago Would Have Delivered You a 51% Gain
ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders who invested a year ago have seen a 51% gain, outperforming the broader market's 16% return. The company's earnings per share (EPS) grew by 101% in the last twelve months, which is significantly higher than its share price increase, suggesting the market might have cooled on the stock despite strong growth. While short-term performance is positive, the article advises considering the company's fundamentals and potential risks for a comprehensive understanding.
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup
ACADIA Pharmaceuticals (NASDAQ:ACAD) exhibits strong growth momentum and a favorable technical setup, making it an attractive opportunity for investors. The company boasts high short-term earnings and sales momentum, evidenced by a ChartMill High Growth Momentum Rating of 6 and significant EPS growth forecasts. Coupled with a strong technical rating and a clear price consolidation pattern, ACAD is positioned for a potential breakout.
Is Acadia’s 2028 Sales Target and DAYBUE STIX Launch Altering The Investment Case For ACADIA (ACAD)?
Acadia Pharmaceuticals recently outlined its long-range plans at the J.P. Morgan Healthcare Conference, projecting US$1.70 billion in combined net sales by 2028 from NUPLAZID and DAYBUE, alongside the phased U.S. launch of DAYBUE STIX. This update reinforces existing expectations for reducing NUPLAZID revenue concentration and developing a strong rare-disease franchise. However, investors should be mindful of increasing R&D and SG&A spending across its numerous active programs.
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness
ACADIA Pharmaceuticals (ACAD) has experienced mixed share price returns, with a recent decline over 7 and 30 days but strong 1-year and 3-year performance. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 70.2%, with a projected intrinsic value of $88.79 per share compared to its current price of $26.46. The company's P/E ratio of 17.14x is also below industry averages and its proprietary "Fair Ratio," indicating potential undervaluation on an earnings basis.
Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges
Acadia Pharmaceuticals' stock fell significantly after its experimental drug for Fragile X syndrome failed to meet its primary endpoint in a phase 3 clinical trial. Conversely, Soleno Therapeutics saw a substantial stock increase after announcing positive data from a late-stage study of its drug for Prader-Willi syndrome. These events highlight the high-risk, high-reward nature of drug development in genetic diseases, impacting company valuations based on trial outcomes.
